MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Verve Therapeutics Inc

Atidarymo kaina

5.79 4.14

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.51

Max

5.93

Pagrindiniai rodikliai

By Trading Economics

Pajamos

98K

-50M

Pardavimai

6.2M

13M

Pelnas, tenkantis vienai akcijai

-0.58

Pelno marža

-382.531

Darbuotojai

274

EBITDA

789K

-54M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+361.61% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-171M

424M

Ankstesnė atidarymo kaina

1.65

Ankstesnė uždarymo kaina

5.79

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Verve Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-24 23:54; UTC

Karštos akcijos

Stocks to Watch: Alphabet, Intel, AppFolio

2025-04-24 23:51; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025-04-24 23:37; UTC

Svarbiausios naujienos

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025-04-24 23:36; UTC

Svarbiausios naujienos

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025-04-24 23:13; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025-04-24 23:09; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025-04-24 22:51; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025-04-24 22:48; UTC

Svarbiausios naujienos

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025-04-24 22:47; UTC

Rinkos pokalbiai

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025-04-24 22:38; UTC

Rinkos pokalbiai
Uždarbis

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025-04-24 22:24; UTC

Rinkos pokalbiai
Uždarbis

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025-04-24 22:23; UTC

Uždarbis

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025-04-24 22:09; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025-04-24 22:00; UTC

Rinkos pokalbiai
Uždarbis

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025-04-24 21:39; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025-04-24 21:23; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025-04-24 21:04; UTC

Uždarbis

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025-04-24 21:02; UTC

Uždarbis

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Akcijų palyginimas

Kainos pokytis

Verve Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

361.61% į viršų

12 mėnesių prognozė

Vidutinis 25.25 USD  361.61%

Aukščiausias 39 USD

Žemiausias 15 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Verve Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.78 / 5.9576Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.